3rd Annual International Congress on the Future of Neurology®

Release Date: October 27, 2021
Expiration Date: October 27, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in neurologic disorders. In this program, these experts present practice-changing clinical data, discuss strategies for incorporating new therapies into clinical practice, and provide a comprehensive overview of pharmacologic and nonpharmacologic modalities to treat neurologic disorders.

Acknowledgement of Commercial Support

This activity is supported by Physicians' Education Resource®.
 

Target Audience

The target audience for this activity is physicians who treat patients with neurologic disorders. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the management of patients with neurologic disorders are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Outline current and emerging diagnostic concepts for neurologic disorders
• Explain clinical evidence for the management of neurologic disorders across multiple lines of care
• Summarize the mechanism of action of therapeutic agents used to manage neurologic disorders
• Prepare strategies for early recognition and management of treatment-related toxicities associated with neurologic therapies
• Apply multidisciplinary care strategies for optimizing patient outcomes in the setting of neurologic disorders
• Assess recent landmark data from clinical trials in the context of evolving treatment paradigms in neurology

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^® LLC, have no relevant financial relationships with ineligible entities.
 

Co-Chairs

Fred D. Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant/Research Support: Novartis Pharmaceuticals; Actelion; Biogen; Sanofi; National Multiple Sclerosis Society; National Institutes of Health; Brainstorm Cell Therapeutics; Consultant: Novartis Pharmaceuticals; Teva Pharmaceuticals; Actelion/Janssen Pharmaceuticals; Acorda Therapeutics, Inc.; F. Hoffmann-La Roche/Genentech, Inc.; MedImmune/Viela Bio, Inc.; Receptos/Celgene/Bristol Meyers Squibb; TG Therapeutics; MedDay Pharmaceuticals; Atara Biotherapeutics, Inc.; Mapi-Pharma Ltd.; Apitope International; Orion Biotechnology; Brainstorm Cell Therapeutics; Jazz Pharmaceuticals; GW Pharma; Mylan NV; Immunic Therapeutics; Population Council; Avotres Inc.; Neurogene; Banner Life Sciences; Speakers’ Bureau: Sanofi Genzyme (nonpromotional).

Stephen Silberstein, MD
Professor of Neurology
Director, Jefferson Headache Center
Jefferson University Hospitals
Philadelphia, PA

Disclosures: Stephen Silberstein, MD, has no relevant financial relationships with ineligible companies.

Jessica Ailani, MD, FAHS, FAAN
Professor of Clinical Neurology
Vice Co-Chair, Strategic Planning, MedStar Neurology
Director, Medstar Georgetown Headache Center
MedStar Georgetown University Hospital
Washington, DC

Disclosures: Grant Research Support: AbbVie Inc./Allergan plc, Biohaven Pharmaceutical, Eli Lilly and Company, Satsuma Pharmaceuticals, Zosano Pharma; Consultant: AbbVie Inc./Allergan plc; Alder BioPharmaceuticals, Inc./Lundbeck Inc; Amgen Inc.; Eli Lilly and Company; Axsome Therapeutics; Aeon Biopharma; GlaxoSmithKline; Satsuma Pharmaceuticals; Impel NeuroPharma, Inc; Theranica; Teva Pharmaceuticals; Revance; Biohaven Pharmaceuticals; Speakers' Bureau: AbbVie Inc./Allergan plc; Alder BioPharmaceuticals, Inc./Lundbeck Inc.; Amgen Inc.; Eli Lilly and Company; Teva Pharmaceuticals; Biohaven Pharmaceuticals; Shareholder: Ctrl M Health.

Thomas Brannagan, MD
Professor of Neurology
Director, Peripheral Neuropathy Center
Columbia University Medical Center
New York, NY

Disclosures: Grant/Research Support: Institution has received compensation from Ionis Pharmaceuticals and Alnylam Pharmaceuticals (clinical trials); Consultant: Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Akcea Therapeutics; Speaker’s Bureau: Akcea Therapeutics, Alnylam Pharmaceuticals.

Carolyn Brockington, MD
Assistant Professor of Neurology
Icahn School of Medicine at Mount Sinai
Director, Stroke Center
Mount Sinai West and Mount Sinai Morningside
New York, NY

Disclosures: Carolyn Brockington, MD, has no relevant financial relationships with ineligible companies.

Jessica Caldwell, PhD
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV

Disclosures: Grant/Research Support: Nevada Exploratory Alzheimer’s Disease Research Center (NeVADRC; P20-AG068053; Co-Director of Administrative Core; PI Sabbagh)

Patricia Coyle, MD
Professor and Chair of Neurology
Renaissance School of Medicine
Vice Chair, Clinical Affairs
Founder and Director, MS Comprehensive Care Center
Stony Brook Neurosciences Institute
Stony Brook University Medical Center
Stony Brook, NY

Disclosures: Grant/Research Support: Genentech/Roche; Novartis Pharmaceuticals; Actelion Pharmaceuticals; Alkermes; CorEvitas, LLC; MedDay Pharmaceuticals; National Institute of Neurologic Disorders and Stroke; Consultant: Accordant; Alexion Pharmaceuticals; Bayer; Biogen; Bristol Myers Squibb; Celgene; EMD Serono; Genentech Roche; GlaxoSmithKline; Janssen Pharmaceuticals; Mylan Pharmaceuticals; Novartis Pharmaceuticals; Sanofi Genzyme; TG Therapeutics; Viela Bio, Inc.; Speaker's Bureau: Biogen (nonbranded), Janssen (nonbranded).

Karl Doghramji, MD, FAASM, DFAPA
Professor of Psychiatry, Neurology, and Medicine
Chair, Albert M. Biele, MD, Memorial Lectureship in Psychiatry
Department of Psychiatry and Human Behavior
Jefferson Medical College
Thomas Jefferson University
Program Director, Fellowship in Sleep Medicine
Medical Director, Jefferson Sleep Disorders Center
Jefferson University Hospitals
Philadelphia, PA

Disclosures: Grant/Research Support: Eisai, Teva Pharmaceuticals, Harmony, Inspire; Consultant: Eisai, Jazz, Harmony, Inspire, Pfizer, Merck & Co.; Stock/Shareholder: Merck & Co.

Mitchell S. V. Elkind, MD, MS, MPhil, FAAN, FAHA
Professor of Neurology and Epidemiology
Chief, Division of Neurology Clinical Outcomes Research and Population Sciences
Department of Neurology
Columbia University Irving Medical Center
Vagelos College of Physicians and Surgeons
Mailman School of Public Health
Columbia University
New York, NY

Disclosures: Grant/Research Support: Bristol Myers Squibb-Pfizer Alliance for Eliquis: study drug in kind for trial; Roche Pharmaceuticals: ancillary funding for trial; Other Support: UpToDate: royalties for chapters on cryptogenic stroke.

Andrew Feigin, MD
Professor of Neurology
NYU Grossman School of Medicine
Associate Chair, NYU Network and Clinical Research
Department of Neurology
Executive Director, The Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders
NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: Vaccinex Inc., Prilenia Therapeutics; Consultant: Voyager Therapeutics, Stealth Biotherapeutics; Speaker's Bureau: Kyowa-Kirin.

Daniel Friedman, MD
Professor of Neurology
NYU Grossman School of Medicine
Co-Director, Special Procedures for the Epilepsy Service
Director, Medical, Cardiac and Neurosurgical ICU Epilepsy Monitoring Services
Co-Director, Video-EEG Laboratory
NYU Comprehensive Epilepsy Center
NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: Epitel Inc.; Consultant: Receptor Life Sciences, Neurelis, Epilepsy Study Consortium; Stock/Shareholder: Neuroview Technology

Fiona Gupta, MD
Assistant Professor of Neurology
Icahn School of Medicine at Mount Sinai
Director, Movement Disorders Outreach Program
Mount Sinai Health System
New York, NY

Disclosures: Consultant: Acorda Therapeutics, Sunovion, Amneal Pharmaceuticals, Abbott Laboratories, Kyura Pharmaceuticals, Neurocrine Biosciences.

Melissa L. Heiry, MD
Clinical Assistant Professor
Jefferson University Hospitals
Philadelphia, PA

Disclosures: Melissa L. Heiry, MD, has no relevant financial relationships with ineligible companies.

Stuart Isaacson, MD
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton
Medical Director, Parkinson’s Research and Education Foundation
Boca Raton, FL

Disclosures: Stuart Isaacson, MD, has no relevant financial relationships with ineligible companies.

Richard S. Isaacson, MD
Director and Founder, Alzheimer’s Prevention Clinic
Weill Cornell Memory Disorders Program
Associate Professor of Neurology
Assistant Dean of Faculty Development
Director, Neurology Residency Program
Weill Cornell Medicine and NewYork-Presbyterian Hospital
New York, NY

Disclosures: Consultant: Acadia Pharmaceuticals, Avanair Pharmaceuticals, Biogen, Novo Nordisk, Roche/Genentech.

Christopher Kellner, MD
Assistant Professor of Neurology
Director, Intracerebral Hemorrhage Program
Associate Director, Neurosurgery Residency Program
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant/Research Support: Penumbra; Integra; Cerebrotech Medical Systems; Viz.ai, Inc.; Minnetronix Medical Inc.; Siemens; Stock/Shareholder: Metis Innovative with investments in Synchron, Proprio, and Fluid Biotech.

Pavel Klein, MD
Director
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, MD

Disclosures:Grant/Research Support: CURE/DOD W81XWH-15-2-0069; Consultant: Aquestive Therapeutics, Arvelle Therapeutics, Neurelis, SK Life Sciences, Sunovion, UCB Pharma; Speaker's Bureau: Aquestive Therapeutics, Eisai, Neurelis, Sunovion, SK Life Science, UCB Pharma Other: CEO, PrevEP LLC.

Stephen Krieger, MD, FAAN
Professor of Neurology
Director, Neurology Residency Training Program
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant/Research Support: Biogen, Novartis Pharmaceuticals; Consultant: Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, MedDay Pharmaceuticals, Novartis Pharmaceuticals, Octave, Teva Pharmaceuticals, TG Therapeutics; Speaker's Bureau: nonpromotional speaking with Biogen, EMD Serono, Genentech, Novartis Pharmaceuticals.

Darcy A. Krueger, MD, PhD
Professor of Clinical Pediatrics and Neurology
University of Cincinnati College of Medicine
Director, Tuberous Sclerosis Clinic and Clack Endowed Chair in Tuberous Sclerosis
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Disclosures: Grant/Research Support: National Institutes of Health, TS Alliance, Clack Foundation, Marinus Pharmaceuticals, Jazz Pharmaceuticals, Tavanta Pharmaceuticals; Consultant: REGENXBIO Inc., Nobel Pharma Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Jazz Pharmaceuticals.

Melissa C. Lipford, MD
Assistant Professor and Consultant
Department of Neurology
Center for Sleep Medicine, Pulmonary and Critical Care Medicine
Mayo Clinic
Rochester, MN

Disclosures: Melissa C. Lipford, MD, has no relevant financial relationships with ineligible companies.

Erin Longbrake, MD, PhD
Assistant Professor of Neurology
Director, Fellowship Program, Multiple Sclerosis & Other Inflammatory Brain Disease
Yale Medicine
New Haven, CT

Disclosures: Grant/Research Support: Genentech; Consultant: Genentech, Genzyme, Alexion Pharmaceuticals, Biogen, EMD Serono.

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN
Associate Professor of Neurology
Thomas Jefferson University
Director, Headache Medicine Fellowship Program
Jefferson Headache Center
Vicki & Jack Farber Institute for Neuroscience
Assistant Director, Neurology Fellowship Program
Jefferson University Hospitals
Philadelphia, PA

Disclosures: Avisory Board: Allergan/AbbVie, Zosano Pharma; Speaker: Allergan/AbbVie, Amgen/Novartis, electroCore, Eli Lilly and Co., Supernus, Teva Pharmaceuticals; Cosultant: Alder/Lundbeck, Allergan/AbbVie, Amgen/Novartis, Biohaven, Eli Lilly, Impel, Nēsos Corp. (formerly Vorso Corp.), Supernus, Teva Pharmaceuticals, Theranica, Zosano Pharma; Support: Clinical trial site PI: Zosano Pharma; Editorial Board: Springer, Wolters-Kluwer Health; Contributing author: Massachusetts Medical Society, Springer, Wolters-Kluwer Health.

Lauren R. Natbony, MD
Assistant Clinical Professor
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Lauren R. Natbony, MD, has no relevant financial relationships with ineligible companies.

Anna Pace, MD
Assistant Professor of Neurology
Icahn School of Medicine at Mount Sinai
Director, Headache Medicine Fellowship Program
Director, Transgender Headache Medicine Program
Mount Sinai Headache and Facial Pain Center
New York, NY

Disclosures: Anna Pace, MD, has no relevant financial relationships with ineligible companies.

Jeffrey B. Ratliff, MD
Clinical Assistant Professor of Neurology
Director, Neurology Residency Program
Co-Director, Movement Disorder Center
Jefferson University Hospitals
Philadelphia, PA

Disclosures: Grant/Research Support: American Academy of Neurology Education (grant); Consultant: US WorldMeds, LLC; Speakers’ Bureau: US WorldMeds, Supernus Pharmaceuticals, Neurocrine Biosciences.

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director of Translational Research
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV

Disclosures: Grant/Research Support: National Institutes of Health, Keep Memory Alive Foundation; Consultant: Alzheon, Neurotrope BioScience, Biogen, Cortexyme, Danone, Regeneron, Roche Genentech, Stage 2 Innovations, Acadia Pharmaceuticals; Speaker’s Bureau: Health and Wellness Partners, Joyce Knapp Communications; Stock/Shareholder: Brain Health Inc, NeuroReserve Inc., NeuroTau, Optima Pharmaceuticals, CognitiveHealth Technologies LLC, uMethod Health, Versanum Inc, Athira Pharma.

Carlos H. Schenck, MD
Professor of Psychiatry
University of Minnesota Medical School
Staff Psychiatrist
Minnesota Regional Sleep Disorders Center
Hennepin County Medical Center
Minneapolis, MN

Disclosures: Consultant: Axovant Sciences (3 years, ending December 31, 2020).

Eric Segal, MD
Assistant Professor
Co-Director of Epileptology
Hackensack Meridian School of Medicine
Director, Pediatric Epilepsy
Northeast Regional Epilepsy Group
Hackensack, NJ

Disclosures: Consultant: Encoded Therapeutics, Inc.; Speaker’s Bureau: Zogenix Pharmaceuticals, GW Pharma, Eisai, Lundbeck.

David M. Simpson, MD, FAAN
Professor of Neurology
Director, Clinical Neurophysiology Laboratories
Director, Neuromuscular Diseases Division
Director, Neuro-AIDS Program
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: Allergan, Ipsen, Merz Pharma; Consultant: Allergan, Ipsen, Merz Pharma, Averitas Pharma; Speaker’s Bureau: Averitas Pharma​.

A. Gordon Smith, MD, FAAN
Professor and Chair of Neurology
Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research
Virginia Commonwealth University
Richmond, VA

Disclosures: A. Gordon Smith, MD, FAAN, has no relevant financial relationships with ineligible companies.

Gil I. Wolfe, MD, FAAN
Professor and Chairman
Irvin and Rosemary Smith Chair of Neurology
University at Buffalo Distinguished Professor
Chief of Service
Department of Neurology
Jacobs School of Medicine and Biomedical Sciences
State University of New York at Buffalo
Buffalo, NY

Disclosures: Grant Research Support: argenx, Ra Pharmaceuticals/UCB, Immunovant, National Institute of Neurologic Disorders and Stroke/National Institutes of Health, MG Foundation of America; Consultant: Grifols, Alexion, argenx, Takeda Pharmaceuticals, BPL Therapeutics, UCB; Speaker’s Bureau: Grifols, Alexion.

Physicians' Education Resource^®, LLC (PER^®), uses a blinded peer-review process. The peer reviewer discloses the following:

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.